Human Genome Sciences helped burnish the reputation of its experimental therapy Zalbin as an alternative option for hepatitis C patients. HGS reported that a mid-stage trial demonstrated that a monthly dose of the drug was as effective as the current standard in treating the ailment. The company noted that the data showed that the drug could be an important option for hep C patients with genotypes 2 and 3, which typically are easier to treat than genotype 1. The drug, which has already generated more than $200 million in milestone payments from Novartis, has been through Phase III and has been filed for approval with the FDA. The PDUFA date is October 4. HGS release | Report